China SXT Pharmaceuticals (SXTC) Competitors $1.38 -0.09 (-6.12%) Closing price 09/4/2025 03:59 PM EasternExtended Trading$1.36 -0.02 (-1.81%) As of 09/4/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SXTC vs. GHRS, KALV, KURA, TYRA, SNDL, IMTX, BCAX, RZLT, MRVI, and TERNShould you be buying China SXT Pharmaceuticals stock or one of its competitors? The main competitors of China SXT Pharmaceuticals include GH Research (GHRS), KalVista Pharmaceuticals (KALV), Kura Oncology (KURA), Tyra Biosciences (TYRA), SNDL (SNDL), Immatics (IMTX), Bicara Therapeutics (BCAX), Rezolute (RZLT), Maravai LifeSciences (MRVI), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry. China SXT Pharmaceuticals vs. Its Competitors GH Research KalVista Pharmaceuticals Kura Oncology Tyra Biosciences SNDL Immatics Bicara Therapeutics Rezolute Maravai LifeSciences Terns Pharmaceuticals GH Research (NASDAQ:GHRS) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends. Do insiders & institutionals have more ownership in GHRS or SXTC? 56.9% of GH Research shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, GHRS or SXTC? GH Research has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Do analysts prefer GHRS or SXTC? GH Research presently has a consensus target price of $32.00, indicating a potential upside of 127.76%. Given GH Research's stronger consensus rating and higher possible upside, equities analysts plainly believe GH Research is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer GHRS or SXTC? In the previous week, GH Research had 9 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 9 mentions for GH Research and 0 mentions for China SXT Pharmaceuticals. GH Research's average media sentiment score of 0.81 beat China SXT Pharmaceuticals' score of 0.00 indicating that GH Research is being referred to more favorably in the media. Company Overall Sentiment GH Research Positive China SXT Pharmaceuticals Neutral Is GHRS or SXTC more profitable? China SXT Pharmaceuticals' return on equity of 0.00% beat GH Research's return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -16.71% -16.06% China SXT Pharmaceuticals N/A N/A N/A Which has higher earnings and valuation, GHRS or SXTC? China SXT Pharmaceuticals has higher revenue and earnings than GH Research. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$38.96M-$0.74-18.99China SXT Pharmaceuticals$1.74M92.02-$3.30MN/AN/A SummaryGH Research beats China SXT Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get China SXT Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTC vs. The Competition Export to ExcelMetricChina SXT PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$170.56M$2.55B$5.76B$9.85BDividend YieldN/A49.35%6.67%4.51%P/E RatioN/A22.9075.7126.43Price / Sales92.02714.55548.17119.09Price / CashN/A169.7737.0558.92Price / Book0.065.3911.296.06Net Income-$3.30M$32.95M$3.29B$266.28M7 Day Performance-5.48%1.08%0.18%-0.32%1 Month Performance-12.66%6.32%6.30%3.44%1 Year Performance-70.66%-0.28%56.91%23.11% China SXT Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTCChina SXT PharmaceuticalsN/A$1.38-6.1%N/A-71.3%$170.56M$1.74M0.0090Gap UpHigh Trading VolumeGHRSGH Research2.436 of 5 stars$13.02-1.2%$32.00+145.8%+65.9%$677.43MN/A-17.5910News CoverageKALVKalVista Pharmaceuticals4.0501 of 5 stars$13.13+1.0%$26.29+100.3%+17.6%$659.76MN/A-3.55100News CoverageKURAKura Oncology3.8371 of 5 stars$7.59-0.8%$24.10+217.7%-59.0%$658.38M$53.88M-3.36130News CoveragePositive NewsAnalyst ForecastTYRATyra Biosciences2.7652 of 5 stars$12.27+2.3%$30.83+151.3%-43.0%$653.99MN/A-6.8920News CoveragePositive NewsAnalyst ForecastSNDLSNDL3.4933 of 5 stars$2.45+1.9%$4.00+63.6%+20.8%$646.69M$944.25M-9.112,516News CoverageAnalyst ForecastIMTXImmatics2.4227 of 5 stars$5.26+0.6%$14.67+178.8%-49.1%$639.96M$130.13M-8.10260Positive NewsBCAXBicara Therapeutics2.5936 of 5 stars$11.58+2.3%$32.25+178.6%N/A$628.24MN/A-3.6332Positive NewsRZLTRezolute3.1664 of 5 stars$7.08+1.1%$12.20+72.3%+57.0%$619.41MN/A-6.1940News CoveragePositive NewsAnalyst ForecastMRVIMaravai LifeSciences3.6883 of 5 stars$2.42+0.6%$5.75+138.1%-71.1%$615.51M$219.83M-1.78610Positive NewsOptions VolumeTERNTerns Pharmaceuticals3.9601 of 5 stars$7.02+4.9%$15.63+122.7%-3.7%$614.33MN/A-6.7540News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies GH Research Alternatives KalVista Pharmaceuticals Alternatives Kura Oncology Alternatives Tyra Biosciences Alternatives SNDL Alternatives Immatics Alternatives Bicara Therapeutics Alternatives Rezolute Alternatives Maravai LifeSciences Alternatives Terns Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SXTC) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China SXT Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China SXT Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SXTC Stock Alerts